Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML

Bone Marrow Transplantation volume 39, pages 725–726 (2007)Cite this article

A 42-year-old previously healthy woman presented in 1990 with anemia and thrombocytopenia and a marrow exam, which showed 95% replacement with myeloblasts. She underwent induction therapy with daunorubicin, ARA-C and thioguanine per Eastern Cooperative Oncology Group protocol, P-C486. Because of the persistence of blasts on day 14 of treatment, she underwent a second induction with daunorubicin and ARA-C alone and was discharged home after count recovery.

Delayed hematologic complications post-transplant, such as myelodysplasia or acute myeloid leukemia (AML) have been well described, whereas the development of a myeloproliferative disorder post transplant is much less common.1 JAK2V617F is a somatic point mutation seen in more than 90% of polycythemia vera patients and approximately 40–50% of patients with either essential thrombocythemia or idiopathic myelofibrosis.2 Although low levels of the JAK2V617F mutation have been reported in healthy individuals, the incidence of the mutation in de novo AML is quite low.3, 4, 5 Also, the presence of JAK2V617F in a single individual over a 15-year period during which both AML and essential thrombocythemia (ET) have been manifested has also not been described previously.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Negrin R, Blume K . Principles of hematopoietic cell transplantation. In: Lichtman MA (ed). Williams Hematology. The McGraw-Hill Companies Inc: New York, 2006, pp 301–322.

    Google Scholar 

  2. Wolanskyj AP, Lasho TL, Schwager SM, McClure F, Wadleigh M, Lee S et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213.

    Article  CAS  Google Scholar 

  3. Lee J, Kim Y, Soung Y, Han K, Kim S, Rhim H et al. The JAK2 V617 mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25: 1434–1436.

    Article  CAS  Google Scholar 

  4. Levine RL, Loriaux M, Huntly BJ, Loh M, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.

    Article  CAS  Google Scholar 

  5. Sidon P, El Housni H, Dessars B, Heimann P . The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Hematology/Oncology Division, University of Rochester, Rochester, NY, USA

    A R Walker, P G Rothberg & J L Liesveld

Authors
  1. A R Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P G Rothberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J L Liesveld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A R Walker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walker, A., Rothberg, P. & Liesveld, J. A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant 39, 725–726 (2007). https://doi.org/10.1038/sj.bmt.1705647

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705647

Search

Advanced search

Quick links